The University of Rochester is a health and research institute ideally suited to help achieve the goals of the Southwest Oncology Group (SWOG). These goals include: improve standards of care to adult cancer patients advance the understanding of cancer biology via translational research, promote treatment and supportive care to outreach sites through NCI-supported clinical trial participation, explore innovative multi-modality treatment combinations, support cancer prevention efforts, and refine methodology of clinical cancer trials. Our long standing history (1978 - 2001) as NCI funded members of the Eastern Cooperative Oncology Group and current activity (2002 - to date) as funded members of the Southwest Oncology Group, indicates our continuous investment in and commitment to clinical and basic laboratory research, patient care, and education. In only one year, we have enrolled 71 cases (100% timely data submission) and served as study chair or co-chair of nine SWOG protocols;27 multidisciplinary members actively participated in one or more committees (two faculty members served as chair and/or co-chair of five committees). Seven faculty members coordinated two protocols to be activated and two studies currently in development. As we recruit more clinical-scientific faculty and further develop interactive, collaborative, multimodality cancer programs, we plan to produce additional important contributions to SWOG. The University of Rochester SWOG program involves: 1) the University's James P. Wilmot Cancer Center and the University's Strong Memorial Hospital, a primary tertiary care center. The Cancer Center and hospital serves a population of approximately 1.4 million people;2) eight outreach facilities located in the regional Northeast section of the country (contiguous states of New York and Massachusetts). Through this Southwest Oncology Group application, our program proposes to support and attain its objectives to 1) participate in multi-modal Phase II/III clinical trials;2) accelerate the advances of cancer therapy in adult patients through increased recruitment;3) enhance basic science clinical interactions;4) support cancer control and prevention initiatives;5) provide wide dissemination of information through quality and timely data collection and publications;6) continue service to the administrative agenda of the Southwest Oncology Group.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA011083-42
Application #
7586594
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1978-06-01
Project End
2009-12-31
Budget Start
2009-01-01
Budget End
2009-12-31
Support Year
42
Fiscal Year
2009
Total Cost
$359,154
Indirect Cost
Name
University of Rochester
Department
Internal Medicine/Medicine
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Rimsza, Lisa M; Li, Hongli; Braziel, Rita M et al. (2018) Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica 103:e151-e153
Chen, Robert W; Li, Hongli; Bernstein, Steven H et al. (2017) RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol 176:759-769
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662

Showing the most recent 10 out of 222 publications